MF Researcher Database

Researcher Database

Advance

Ohmori Tohru

■FacultyRespiratory and Allergy
■Position
Last Updated :2025/04/01

Researcher

基本情報

Profile and Settings

  • 氏名

    Ohmori Tohru

Affiliation

  • Respiratory and Allergy

Location

  • University Hospital

Degree

  • Doctor of Medical Science, Showa University, Oct. 1994

Achievements

Published Papers

  • Comparative Efficacy and Safety of Lorlatinib and Alectinib for ALK-Rearrangement Positive Advanced Non-Small Cell Lung Cancer in Asian and Non-Asian Patients: A Systematic Review and Network Meta-Analysis, ANDO Koichi;MANABE Ryo;KISHINO Yasunari;KUSUMOTO Sojiro;YAMAOKA Toshimitsu;TANAKA Akihiko;OHMORI Tohru;SAGARA Hironori, Cancers (Basel), 13(15):3704, Jul. 2021, Peer-reviewed
  • Comparative Efficacy and Safety of Immunotherapeutic Regimens with PD-1/PD-L1 Inhibitors for Previously Untreated Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis., ANDO Koichi;MANABE Ryo;KISHINO Yasunari;KUSUMOTO Sojiro;YAMAOKA Toshimitsu;TANAKA Akihiko;OHMORI Tohru;OHNISHI Tsukasa;SAGARA Hironori, Curr Oncol, 28(2):1094 - 1113, Feb. 2021, Peer-reviewed
  • Molecular and Clinical Features of EGFR-TKI-Associated Lung Injury., OHMORI Tohru;YAMAOKA Toshimitsu;ANDO Koichi;KUSUMOTO Sojiro;KISHINO Yasunari;MANABE Ryo;SAGARA Hironori, Int J Mol Sci, 22(2):792, Jan. 2021, Peer-reviewed
  • HER2-D16 oncogenic driver mutation confers osimertinib resistance in EGFR mutation-positive non-small cell lung cancer., YAMAOKA Toshimitsu;TSURUTANI Junji;SAGARA Hironori;OHMORI Tohru, Transl Lung Cancer Res, 9(5):2178 - 2183, Oct. 2020
  • Correlation of Arterial CO2 and Respiratory Impedance Values among Subjects with COPD., UNO Tomoki;HOMMA Tetsuya;SHIGEMURA Masahiko;FUKUDA Yosuke;KIMURA Tomoyuki;ONITSUKA Chisato;KAWAHARA Tomoko;SATO Hiroki;AKIMOTO Kaho;SUGANUMA Hiromitsu;KASHIMA Ayaka;YAMAMOTO Shigenori;EBATO Takaya;MATSUNAGA Tomohiro;KANEKO Keisuke;MIKUNI Hatsuko;SATO Haruna;UCHIDA Yoshitaka;FUJIWARA Akiko;KUWAHARA Naota;MANABE Ryo;IDA Hitomi;HIRAI Kuniaki;MIYATA Yoshito;JINNO Megumi;OHTA Shin;KISHINO Yasunari;INOUE Hideki;YAMAMOTO Mayumi;WATANABE Yoshio;KUSUMOTO Sojiro;ANDO Koichi;SUZUKI Shintaro;TANAKA Akihiko;OHMORI Tohru;SAGARA Hironori, J Clin Med, 9(9):2819, Aug. 2020, Peer-reviewed
  • Nivolumab plus Ipilimumab versus Existing Immunotherapies in Patients with PD-L1-Positive Advanced Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis., ANDO Koichi;KISHINO Yasunari;HOMMA Tetsuya;KUSUMOTO Sojiro;YAMAOKA Toshimitsu;TANAKA Akihiko;OHMORI Tohru;OHNISHI Tsukasa;SAGARA Hironori, Cancers (Basel), 12(7):1905, Jul. 2020, Peer-reviewed
  • Brigatinib and Alectinib for ALK Rearrangement-Positive Advanced Non-Small Cell Lung Cancer With or Without Central Nervous System Metastasis: A Systematic Review and Network Meta-Analysis., ANDO Koichi;AKIMOTO Kaho;SATO Hiroki;MANABE Ryo;KISHINO Yasunari;HOMMA Tetsuya;KUSUMOTO Sojiro;YAMAOKA Toshimitsu;TANAKA Akihiko;OHMORI Tohru;SAGARA Hironori, Cancers (Basel), 12(4):942, Apr. 2020, Peer-reviewed
  • Inhibition of Virus-Induced Cytokine Production from Airway Epithelial Cells by the Late Addition of Budesonide., HOMMA Tetsuya;FUKUDA Yosuke;UCHIDA Yoshitaka;UNO Tomoki;JINNO Megumi;KISHINO Yasunari;YAMAMOTO Mayumi;SATO Hiroki;AKIMOTO Kaho;KANEKO Keisuke;FUJIWARA Akiko;SATO Haruna;HIRAI Kuniaki;MIYATA Yoshito;INOUE Hideki;OHTA Shin;WATANABE Yoshio;KUSUMOTO Sojiro;ANDO Koichi;SUZUKI Shintaro;YAMAOKA Toshimitsu;TANAKA Akihiko;OHMORI Tohru;SAGARA Hironori, Medicina (Kaunas), 56(3):98, Feb. 2020, Peer-reviewed
  • Blockade of EGFR Activation Promotes TNF-Induced Lung Epithelial Cell Apoptosis and Pulmonary Injury., YAMAOKA Toshimitsu;ARATA Satoru;HOMMA Mayumi;HOMMA Tetsuya;KUSUMOTO Sojiro;ANDO Koichi;MANABE Ryo;KISHINO Yasunari;OHBA Motoi;TSURUTANI Junji;TAKIMOTO Masafumi;OHMORI Tohru;SAGARA Hironori, Int J Mol Sci, 20(16):E4021, Aug. 2019, Peer-reviewed
  • Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib., YAMAOKA Toshimitsu;OHBA Motoi;MATSUNAGA Yuki;TSURUTANI Junji;OHMORI Tohru, J Vis Exp, (148):e, Jun. 2019, Peer-reviewed
  • KRAS and EGFR Amplifications Mediate Resistance to Rociletinib and Osimertinib in Acquired Afatinib-Resistant NSCLC Harboring Exon 19 Deletion/T790M in EGFR., NAKATANI Kaori;YAMAOKA Toshimitsu;OHBA Motoi;FUJITA Ken-ichi;ARATA Satoru;KUSUMOTO Sojiro;TAKI (TAKEMOTO) Iori;KAMEI Daisuke;IWAI Shinichi;TSURUTANI Junji;OHMORI Tohru, Mol Cancer Ther, 18(1):112 - 126, Jan. 2019, Peer-reviewed
  • Receptor Tyrosine Kinase-Targeted Cancer Therapy., YAMAOKA Toshimitsu;KUSUMOTO Sojiro;ANDO Koichi;OHBA Motoi;OHMORI Tohru, Int J Mol Sci, 19(11):E3491, Nov. 2018, Peer-reviewed
  • Efficacy and Safety of Long-acting Beta-2 Agonist and Long-acting Muscarinic Antagonist Combinations in Patients with Chronic Obstructive Pulmonary Disease: Meta-analysis of Phase 3 Randomized Trials, ANDO Koichi;TANAKA Akihiko;KUSUMOTO Sojiro;YAMAOKA Toshimitsu;OHMORI Tohru;OHNISHI Tsukasa;INOUE Shin;SAGARA Hironori, Showa Univ J Med Sci, 30(2):159 - 174, Jun. 2018, Peer-reviewed, DOI:10.15369/sujms.30.159
  • Alectinib Versus Crizotinib for Previously Untreated Alk-positive Advanced Non-small Cell Lung Cancer : A Meta-Analysis, MANABE Ryo;ANDO Koichi;KUSUMOTO Sojiro;TANAKA Akihiko;YAMAOKA Toshimitsu;OHMORI Tohru;OHNISHI Tsukasa;SAGARA Hironori, Showa Univ J Med Sci, 30(2):309 - 315, Jun. 2018, Peer-reviewed
  • Comparative Efficacy and Safety of Anti-Interleukin-5 Therapies and Placebo in Patients with Uncontrolled Eosinophilic Asthma:A Systematic Review and Meta-analysis of Phase 3 Trials, ANDO Koichi;TANAKA Akihiko;KUSUMOTO Sojiro;YAMAOKA Toshimitsu;OHMORI Tohru;INOUE Shin;SAGARA Hironori, Showa Univ J Med Sci, 30(1):11 - 25, Mar. 2018, Peer-reviewed, DOI:10.15369/sujms.30.11
  • A Long-acting Muscarinic Antagonist （LAMA） Added to an Inhaled Corticosteroid and Long-acting Beta-2 Agonist Versus LAMA Alone in Moderate-to-severe Chronic Obstructive Pulmonary Disease:A Systematic Review and Meta-analysis of Randomized Trials, ANDO Koichi;TANAKA Akihiko;KUSUMOTO Sojiro;YAMAOKA Toshimitsu;OHMORI Tohru;OHNISHI Tsukasa;INOUE Shin;SAGARA Hironori, Showa Univ J Med Sci, 30(1):1 - 9, Mar. 2018, Peer-reviewed, DOI:10.15369/sujms.30.1
  • EGFR-TKI Versus Chemotherapy for Previously Untreated Advanced Non-Small Cell Lung Cancer in Asians: A Meta-Analysis, ANDO Koichi;KUSUMOTO Sojiro;TANAKA Akihiko;YAMAOKA Toshimitsu;OHMORI Tohru;OHNISHI Tsukasa;INOUE Shin;SAGARA Hironori, Showa Univ J Med Sci, 29(4):435 - 443, Dec. 2017, Peer-reviewed, DOI:10.15369/sujms.29.435
  • Molecular-Targeted Therapies for Epidermal Growth Factor Receptor and Its Resistance Mechanisms, YAMAOKA Toshimitsu;OHBA Motoi;OHMORI Tohru, Int J Mol Sci, 18(11):2420, Nov. 2017, Peer-reviewed
  • A Comparison of Adverse Effect Profiles of Two Anti-IL-5 Therapies in Adults with Uncontrolled Asthma―A Network Meta-analysis of Phase 3 Trials―, ANDO Koichi;MIYATA Yoshito;HIRAI Kuniaki ;MIZUMA Hiroko ;YAMAGUCHI Munehiro;MURATA Yasunori;HOMMA Tetsuya;OHTA Shin;YAMAMOTO Mayumi;KUSUMOTO Sojiro;YAMAOKA Toshimitsu;TANAKA Akihiko;YOKOE Takuya;OHNISHI Tsukasa;OHMORI Tohru;INOUE Shin;SAGARA Hironori, Showa Univ J Med Sci, 29(3):279 - 287, Sep. 2017, Peer-reviewed
  • Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure., YAMAOKA Toshimitsu;OHBA Motoi;ARATA Satoru;OHMORI Tohru, J Vis Exp, (126):e, Aug. 2017, Peer-reviewed
  • Distinct Afatinib Resistance Mechanisms Identified in Lung Adenocarcinoma Harboring an EGFR Mutation, YAMAOKA Toshimitsu;OHMORI Tohru;OHBA Motoi;ARATA Satoru;MURATA Yasunori;KUSUMOTO Sojiro;ANDO Koichi;ISHIDA Hiroo;OHNISHI Tsukasa;SASAKI Yasutsuna, Mol Cancer Res, 15(7):915 - 928, Jul. 2017, Peer-reviewed
  • Comparing the Adverse Event Profiles of Nivolumab and Docetaxel in Previously-treated or Refractory Advanced Non-small Cell Lung Cancer: A Meta-analysis of Two Phase 3 Trials, ANDO Koichi;MURATA Yasunori;KUSUMOTO Sojiro;YAMAOKA Toshimitsu;TANAKA Akihiko;YOKOE Takuya;OKUDA Kentaro ;OHNISHI Tsukasa;INOUE Shin;OHMORI Tohru;SAGARA Hironori, Showa Univ J Med Sci, 29(1):69 - 77, Mar. 2017, Peer-reviewed, DOI:10.15369/sujms.29.69
  • Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI-Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation., YAMAOKA Toshimitsu;OHMORI Tohru;OHBA Motoi;ARATA Satoru;KISHINO Yasunari;MURATA Yasunori;KUSUMOTO Sojiro;ISHIDA Hiroo;SHIRAI Takao;HIROSE Takashi;OHNISHI Tsukasa;SASAKI Yasutsuna, Mol Cancer Ther, 15(12):3040 - 3054, Dec. 2016, Peer-reviewed
  • Long-term prognostic impact of circulating tumour cells in gastric cancer patients., ITO Hiroaki;SATO Jun;TSUJINO Yukio;YAMAGICHI Noriko;KIMURA Satoshi;GOHDA Keigo;MURAKAMI Katsuhiro;ONIMARU Manabu;OHMORI Tohru;ISHIKAWA Fumihiro;INOUE Haruhiro, World J Gastroenterol, 22(46):10232 - 10241, Dec. 2016, Peer-reviewed
  • Change in number and size of circulating tumor cells with high telomerase activity during treatment of patients with gastric cancer., ITO Hiroaki;YAMAGUCHI Noriko;ONIMARU Manabu;KIMURA Satoshi;OHMORI Tohru;ISHIKAWA Fumihiro;SATO Jun;ITO Shun;INOUE Haruhiro, Oncol Lett, 12(6):4720 - 4726, Dec. 2016, Peer-reviewed
  • Association of pharmacokinetics and pharmacogenomics with safety and efficacy of gefitinib in patients with EGFR mutation positive advanced non-small cell lung cancer, HIROSE Takashi;FUJITA Ken-ichi;KUSUMOTO Sojiro;OKI Yasunari;MURATA Yasunori;SUGIYAMA Tomohide;ISHIDA Hiroo;SHIRAI Takao;NAKASHIMA Masanao;YAMAOKA Toshimitsu;OKUDA Kentaro;OHMORI Tohru;SASAKI Yasutsuna, Lung Cancer, 93:69 - 76, Mar. 2016, Peer-reviewed
  • Up-regulation of Syndecan-4 contributes to TGF-β1-induced epithelial to mesenchymal transition in lung adenocarcinoma A549 cells, TOBA-ICHIHASHI Yoko;YAMAOKA Toshimitsu;OHMORI Tohru;OHBA Motoi, Biochem Biophys Rep, 5:1 - 7, Nov. 2015, Peer-reviewed
  • Up-regulation of Syndecan-4 contributes to TGF-β1-induced epithelial to mesenchymal transition in lung adenocarcinoma A549 cells., TOBA-ICHIHASHI Yoko;YAMAOKA Toshimitsu;OHMORI Tohru;OHBA Motoi, Biochem Biophys Rep, 5:1 - 7, Nov. 2015, Peer-reviewed
  • Prognostic impact of the number of viable circulating cells with high telomerase activity in gastric cancer patients: A prospective study, ITO Hiroaki;INOUE Haruhiro;KIMURA Satoshi;OHMORI Tohru;ISHIKAWA Fumihiro;GOHDA Keigo;SATO Jun, Int J Oncol, 45(1):227 - 234, Jul. 2014, Peer-reviewed
  • Phase II study of concurrent chemoradiotherapy with carboplatin and vinorelbine for locally advanced non-small-cell lung cancer., ISHIDA Koko;HIROSE Takashi;YOKOUCHI Junichi ;OKI Yasunari;KUSUMOTO Sojiro;SUGIYAMA Tomohide;ISHIDA Hiroo;SHIRAI Takao;NAKASHIMA Masanao;YAMAOKA Toshimitsu;OHNISHI Tsukasa;OHMORI Tohru;KAGAMI Yoshikazu, Mol Clin Oncol, 2(3):405 - 410, May 2014, Peer-reviewed
  • Evaluation of the safety and efficacy of combination chemotherapy with vinorelbine and platinum agents for patients with non-small cell lung cancer with interstitial lung disease., OKUDA Kentaro;HIROSE Takashi;OKI Yasunari;MURATA Yasunori;KUSUMOTO Sojiro;SUGIYAMA Tomohide;ISHIDA Hiroo;SHIRAI Takao;NAKASHIMA Masanao;YAMAOKA Toshimitsu;OHNISHI Tsukasa;OHMORI Tohru, Anticancer Res, 32(12):5475 - 5480, Dec. 2012, Peer-reviewed
  • MET increases the sensitivity of gefitinib-resistant cells to SN-38, an active metabolite of irinotecan, by up-regulating the topoisomerase I activity., SAKAI Asao;KASAHARA Kazuo;OHMORI Tohru;KIMURA Hideharu;SONE Takashi;FUJIMURA Masaki;NAKAO Shinji, J Thorac Oncol, 7(9):1337 - 1344, Sep. 2012, Peer-reviewed
  • 進行再発非小細胞肺癌に対するセカンドライン化学療法の検討, 白井　崇生;廣瀬　敬;村田　泰規;大木　康成;楠本　壮二郎;杉山　智英;石田　博雄;中嶌　賢尚;大西　司;山岡　利光;大森　亨;奥田　健太郎, 昭和医学会雑誌, 72(4):446 - 452, Aug. 2012, Peer-reviewed, DOI:10.14930/jsma.72.446
  • Relationship of circulating tumor cells to the effectiveness of cytotoxic chemotherapy in patients with metastatic non-small-cell lung cancer., HIROSE Takashi;MURATA Yasunori;OKI Yasunari;SUGIYAMA Tomohide;KUSUMOTO Sojiro;ISHIDA Hiroo;SHIRAI Takao;NAKASHIMA Masano;山岡　利光;OKUDA Kentaro;OHNISHI Tsukasa;OHMORI Tohru, Oncol Res, 20(2月3日):131 - 137, Feb. 2012, Peer-reviewed

Presentations

  • EGFR遺伝子変異を有する肺腺癌細胞PC-9における第３世代EGFR-TKI, オシメルチニブの獲得耐性機序の検討, 山岡　利光;岸野　康成;楠本　壮二郎;安藤　浩一;大森　亨;相良　博典;鶴谷　純司, 第62回日本肺癌学会学術集会, 27 Nov. 2021, 横浜・LIVE配信・オンデマンド配信
  • Comparative Efficacy and Safety of Immunotherapeutic Regimens with PD-1/PD-L1 Inhibitors for ES-SCLC, 安藤　浩一;岸野　康成;楠本　壮二郎;山岡　利光;田中　明彦;大森　亨;相良　博典, 第62回日本肺癌学会学術集会, 27 Nov. 2021, 横浜およびWEB配信
  • Mechanism of resistance to third-generation EGFR-TKI, osimertinib, in lung adenocarcinoma PC-9 cells, 山岡　利光;岸野　康成;楠本　壮二郎;安藤　浩一;大森　亨;相良　博典;鶴谷　純司, 第80回⽇本癌学会学術総会, 02 Oct. 2021, 横浜
  • 慢性閉塞性肺疾患における"Adherence Starts with Knowledge-20 (ASK-20)" 質問票と臨床因子の関連性, 秋本　佳穂;平井　邦朗;佐藤　裕基;三國　肇子;河原　朋子;佐藤　春奈;宇野　知輝;内田　嘉隆;福田　陽佑;木村　友之;神野　恵美;岸野　康成;大田　進;本間　哲也;井上　英樹;山本　真弓;渡部　良雄;楠本　壮二郎;安藤　浩一;鈴木　慎太郎;田中　明彦;大森　亨;相良　博典, 第61回日本呼吸器学会学術講演会, 25 Apr. 2021, 東京およびオンデマンド配信
  • 体幹部定位放射線治療による肺合併症の実際, 楠本　壮二郎;岸野　康成;小林　玲;安藤　浩一;久保田　祐太郎;村上　幸三;堀池　篤;大森　亨;伊藤　芳紀;角田　卓也;相良　博典, 第61回日本肺癌学会学術集会, 14 Nov. 2020, 岡山およびライブ配信・オンデマンド配信
  • PS良好PD-L1高発現NSCLCに対するPembrolizumab療法とプラチナ製剤併用＋Pembrolizumab療法の有効性の検討, 岸野　康成;楠本　壮二郎;堀池　篤;有泉　裕嗣;久保田　祐太郎;安藤　浩一;田中　明彦;大森　亨;角田　卓也;相良　博典, 第61回日本肺癌学会学術集会, 12 Nov. 2020, 岡山およびライブ配信・オンデマンド配信
  • 胸部放射線療法と免疫チェックポイント阻害薬での肺合併症の実際, 佐藤　裕基;楠本　壮二郎;眞鍋　亮;平井　邦朗;江波戸　貴哉;松永　智宏;宇野　知輝;伊田　瞳;木村　友之;神野　恵美;宮田　祐人;岸野　康成;加藤　正子;安藤　浩一;村上　幸三;田中　明彦;大森　亨;伊藤　芳紀;相良　博典, 第60回日本呼吸器学会学術講演会, 21 Sep. 2020, Web開催
  • EGFRチロシンキナーゼ阻害剤によるSPC-TNFトランスジェニックマウスにおける肺組織損傷とアポトーシス誘導機序の検討, 山岡　利光;大森　亨;安藤　浩一;楠本　壮二郎;本間　哲也;岸野　康成;眞鍋　亮;相良　博典;鶴谷　純司, 第60回日本呼吸器学会学術講演会, 20 Sep. 2020, Web開催
  • 化学放射線療法後抗PD-LI抗体薬で生じた肺臓炎に対し、気管支鏡検査を行った局所進行非小細胞癌2症例の検討, 楠本　壮二郎;菅沼　宏充;賀嶋　絢佳;江波戸　貴哉;松永　智宏;佐藤　春奈;伊田　瞳;眞鍋　亮;小林　玲;岸野　康成;安藤　浩一;村上　幸三;田中　明彦;大森　亨;伊藤　芳紀;相良　博典, 第43回日本呼吸器内視鏡学会学術集会, 27 Jun. 2020, 紙上開催
  • 呂律障害、嚥下障害で頭蓋底斜台部転移と診断された進展型小細胞肺癌の一例, 松永　智宏;楠本　壮二郎;眞鍋　亮;江波戸　貴哉;賀嶋　絢佳;伊田　瞳;岸野　康成;安藤　浩一;村上　孝三;大森　亨;伊藤　芳紀;相良　博典, 第186回日本肺癌学会関東支部学術集会, 14 Dec. 2019, 東京
  • 高齢者非小細胞肺癌に対するImmune checkpoint inhibitorの有効性に関するメタ解析, 安藤　浩一;眞鍋　亮;岸野　康成;楠本　壮二郎;山岡　利光;大森　亨;相良　博典, 第60回日本肺癌学会学術集会, 08 Dec. 2019, 大阪
  • 実臨床でのPD-L1発現検査に関する検討, 楠本　壮二郎;石田　博雄;三浦　咲子;眞鍋　亮;岸野　康成;安藤　浩一;濵田　和幸;山本　滋;大森　亨;瀧本　雅文;武井　秀史;鈴木　隆;角田　卓也;相良　博典, 第60回日本肺癌学会学術集会, 06 Dec. 2019, 大阪
  • 種々の有毛動物に感作していたCat-Pork Syndromeの1例, 鈴木　慎太郎;宇野　知輝;内田　嘉隆;松永　智宏;田中　明彦;大森　亨;大西　司;相良　博典, 第68回日本アレルギー学会学術大会, 16 Jun. 2019, 東京
  • アニサキスアレルギーによる魚介類摂取制限が脂質代謝に与える影響, 鈴木　慎太郎;松永　智宏;宮田　祐人;宇野　知輝;内田　嘉隆;福田　陽佑;木村　友之;伊田　瞳;眞鍋　亮;桑原　直太;平井　邦明;神野　恵美;岸野　康成;大田　進;本間　哲也;渡部　良雄;山本　真弓;田中　明彦;大森　亨;相良　博典, 第68回日本アレルギー学会学術大会, 15 Jun. 2019, 東京
  • 進行肺癌患者に使用したPEG化G-SCF製剤による大動脈炎の一例, 楠本　壮二郎;木村　友之;眞鍋　亮;神野　恵美;安藤　浩一;田中　明彦;大森　亨;大西　司;相良　博典, 第68回日本アレルギー学会学術大会, 15 Jun. 2019, 東京
  • 難治性アレルギー性鼻炎に対するomalizumabの有効性と安全性の検討-無作為化比較試験のメタ解析-, 安藤　浩一;田中　明彦;本間　哲也;大森　亨;大西　司;相良　博典, 第68回日本アレルギー学会学術大会, 14 Jun. 2019, 東京
  • 軽症気管支喘息患者におけるICS/FABA必要時使用の低用量ICS定期吸入に対する非劣性の解析, 安藤　浩一;田中　明彦;本間　哲也;大森　亨;大西　司;相良　博典, 第68回日本アレルギー学会学術大会, 14 Jun. 2019, 東京
  • KRAS Amplification Mediates Resistance to Osimertinib in Acquired Afatinib-Resistant PC-9 cells Harboring Exon 19 Deletion/T790M in EGFR, 山岡　利光;大森　亨;相良　博典;鶴谷　純司, 第23回日本がん分子標的治療学会学術集会, 13 Jun. 2019, 大阪
  • EGFR遺伝子変異陽性(exon19del/T790M)肺腺癌細胞株におけるオシメルチニブ獲得耐性機序., 山岡　利光, 第59回日本呼吸器学会学術講演会, 12 Apr. 2019, 東京
  • 難治性喘息に対するdupilumabとbenralizumabの有効性と安全性の比較検討-第III相試験のネットワーク・メタ解析-, 安藤　浩一;田中　明彦;山口　宗大;本間　哲也;大森　亨;大西　司;相良　博典, 第59回日本呼吸器学会学術講演会, 12 Apr. 2019, 東京
  • KRAS amplification mediates resistance to osimertinib in acquired afatinib-resistant NSCLC harboring exon 19 deletion/T790M in EGFR., YAMAOKA Toshimitsu;OHBA Motoi;KISHINO Yasunari;KUSUMOTO Sojiro;TSURUTANI Junji;OHMORI Tohru, AACR Annual Meeting 2019, 01 Apr. 2019, Atlanta
  • T790M-EGFRによりアファチニブ耐性をきたした肺腺癌細胞株におけるロシレチニブ耐性機序の検討, 山岡　利光;楠本　壮二郎;安藤　浩一;石田　博雄;大西　司;相良　博典;大森　亨, 第59回日本肺癌学会学術集会, 30 Nov. 2018, 東京
  • SMART療法の有効性の検討-無作為化比較試験のメタ解析-, 安藤　浩一;田中　明彦;本間　哲也;山口　宗大;大西　司;大森　亨;相良　博典, 第82回臨床アレルギー研究会, 24 Nov. 2018, 東京
  • 子宮内膜治療薬ジエノゲストにより誘起されたと推察した血管性浮腫の一例, 鈴木　慎太郎;金子　佳右;宇野　知輝;内田　嘉隆;松永　智宏;福田　陽佑;楠本　壮二郎;伊田　瞳;眞鍋　亮;桑原　直太;宮田　祐人;平井　邦朗;神野　恵美;岸野　康成;木村　友之;本間　哲也;渡部　良雄;大田　進;山口　史博;田中　明彦;大西　司;大森　亨;相良　博典, 第82回臨床アレルギー研究会, 24 Nov. 2018, 東京
  • 多種食物アレルギーに併発した身長促進サプリメントによる肝障害の1例, 鈴木　慎太郎;金子　佳右;宇野　知輝;内田　嘉隆;松永　智宏;福田　陽佑;木村　友之;伊田　瞳;眞鍋　亮;桑原　直太;宮田　祐人;平井　邦朗;神野　恵美;岸野　康成;大田　進;本間　哲也;渡部　良雄;楠本　壮二郎;山口　史博;田中　明彦;大西　司;大森　亨;相良　博典, 第82回臨床アレルギー研究会, 24 Nov. 2018, 東京
  • Evolution of kinase inhibitors sensitivity in three-dimensional suspended spheroid culture platform, ITO Risa;SUZUKI Toshihiro;YAMAOKA Toshimitsu;OHMORI Tohru;NISHIO Kazuto;OGASAWARA Yuki, 第77回日本癌学会学術総会, 28 Sep. 2018, 大阪
  • Mechanism of resistance to third-generation EGFR-TKI, rociletinib, in lung adenocarcinoma cells with EGFR-T790M mutation, YAMAOKA Toshimitsu;NAKATANI Kaori;OHBA Motoi;FUJITA Ken-ichi;ARATA Satoru;IWAI Shinichi;OHMORI Tohru, 第77回日本癌学会学術総会, 28 Sep. 2018, 大阪
  • Resistance mechanisms to third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in lung adenocarcinoma cells harboring the EGFR-T790M mutation, NAKATANI Kaori;YAMAOKA Toshimitsu;OHMORI Tohru;OHBA Motoi;FUJITA Ken-ichi;TAKI Iori;KAMEI Daisuke;IWAI Shinichi;SASAKI Yasutsuna, 18th World Congress of Basic and Clinical Pharmacology (WCP2018), 05 Jul. 2018, Kyoto
  • Resistance mechanisms to third-generation EGFR TKIs in lung adenocarcinoma harboring EGFR T790M mutation, 中谷　香織;山岡　利光;大森　亨;大場　基;藤田　健一;滝　伊織;亀井　大輔;岩井　信市, 日本薬学会第138年会, 28 Mar. 2018, 金沢
  • Dual resistance of EGFR-mutant lung adenocarcinoma cells to EGFR and MET inhibitors, YAMAOKA Toshimitsu;OHMORI Tohru;OHBA Motoi;ARATA Satoru;MURATA Yasunori;KISHINO Yasunari;KUSUMOTO Sojiro;ISHIDA Hiroo;OHNISHI Tsukasa;SASAKI Yasutsuna, 第75回日本癌学会学術総会, 08 Oct. 2016, 横浜
  • Combination effect of afatinib and BI836845, a humanized IGF ligand-neutralizing antibody, on EGFR-TKI-resistant NSCLC, OHMORI Tohru;YAMAOKA Toshimitsu;ARATA Satoru;OHBA Motoi;MURATA Yasunori;KISHINO Yasunari;KUSUMOTO Sojiro;HIROSE Takashi;ONISHI Tsukasa;NISHIO Kazuto, 第75回日本癌学会学術総会, 07 Oct. 2016
  • Mechanism underlying acquisition of dual resistance to EGFR and MET inhibitors by EGFR-mutant lung adenocarcinoma cells, 山岡　利光, 第14回日本臨床腫瘍学会学術集会, 28 Jul. 2016, 神戸
  • The effect of kinase signaling for miR-205 regulation in gefitinib-resistant lung cancer cell lines, SUZUKI Toshihiro;NAGASAWA Ikuko;YAMAOKA Toshimitsu;OHMORI Tohru;NISHIO Kazuto;KOYAMA Kiyotaka;OGASAWARA Yuki, AACR Annual Meeting 2016, 18 Apr. 2016, New Orleans
  • Mechanism underlying acquisition of dual resistance to EGFR and MET inhibitors by EGFR-mutant lung adenocarcinoma cells, YAMAOKA Toshimitsu;OHMORI Tohru;OHBA Motoi;MURATA Yasunori;KISHINO Yasunari;KUSUMOTO Sojiro;ISHIDA Hiroo;OHNISHI Tsukasa;SASAKI Yasutsuna, American Association for Cancer Research Annual Meeting 2016, 18 Apr. 2016, New Orleans
  • Combination effect of afatinib and BI 836845, a humanized IGF ligand-neutralizing antibody, on EGFR-TKI-resistant NSCLC cells, OHMORI Tohru;YAMAOKA Toshimitsu;ARATA Satoru;OHBA Motoi;MURATA Yasunori;KISHIDA Yasunari;KUSUMOTO Sojiro;NAKASHIMA Masanao;HIROSE Takashi;OHNISHI Tsukasa;NISHIO Kazuto, American Association for Cancer Research Annual Meeting 2016, 18 Apr. 2016, New Orleans
  • Mechanism underlying acquisition of dual resistance to EGFR & MET inhibitors by EGFR-mutant lung adenocarcinoma cells, YAMAOKA Toshimitsu;OHMORI Tohru;OHBA Motoi;TOYA Etsuko;KISHINO Yasunari;MURATA Yasunori;KUSUMOTO Sojiro;ISHIDA Hiroo;OHNISHI Tsukasa;SAGARA Hironori;SASAKI Yasutsuna, 第74回日本癌学会学術総会, 09 Oct. 2015, 名古屋
  • Mechanism underlying acquisition of dual resistance to EGFR & MET inhibitors by EGFR-mutant lung adenocarcinoma cells, 山岡　利光;大森　亨;大場　基;外谷　衣都子;岸野　康成;村田　泰規;楠本　壮二郎;石田　博雄;大西　司;相良　博典;佐々木　康綱, 第74回日本癌学会学術総会, 09 Oct. 2015, 名古屋
  • The effect of ErbB3 phosphorylation for miR-205 regulation in gefitinib-resistant lung cancer cell lines, SUZUKI Toshihiro;NAGASAWA Ikuko;YAMAOKA Toshimitsu;OHMORI Tohru;NISHIO Kazuto;KOYAMA Kiyotaka;OGASAWARA Yuki, 第74回日本癌学会学術総会, 08 Oct. 2015, 名古屋
  • Simple blood test for diagnosis of gastrointestinal and pancreas cancer using surface-enhanced Raman scattering, ITO Hiroaki;HASEGAWA Katsuyuki;HASEGAWA Yuuki;KIMURA Satoshi;ONIMARU Manabu;OHMORI Tohru;IKEDA Haruo;SAITO Mitsuo;KITAMURA Yohei;SATO Chiaki;GOMI Kuniyo;SAKAUE Satoshi;ISOZAKI Masayuki;MATSUKAWA Masaaki;INOUE Haruhiro, American Society of Clinical Oncology 2015 Gastrointestinal Cancers Symposium, 15 Jan. 2015, Chicago
  • Association of pharmacokinetics or pharmacogenomics with toxicity of erlotinib in patients with recurrent advanced non-small cell lung cancer., HIROSE Takashi;FUJITA Ken-ichi;KUSUMOTO Sojiro;OKI Yasunari;MURATA Yasunori;SUGIYAMA Tomohide;ISHIDA Hiroo;SHIRAI Takao;NAKASHIMA Masanao;YAMAOKA Toshimitsu;OKUDA Kentaro;OHNISHI Tsukasa;OHMORI Tohru;SASAKI Yasutsuna;TAMURA Atsuhisa;OHTA Ken, The 39th European Society for Medical Oncology annual meeting, 27 Sep. 2014, Madrid
  • The effect of kinase signaling for miR-205 regulation in gefitinib-resistant lung cancer cell lines, SUZUKI Toshihiro;NAGASAWA Ikuko;YAMAOKA Toshimitsu;OHMORI Tohru;NISHIO Kazuto;KOYAMA Kiyoataka;OGASAWARA Yuki, 第73回日本癌学会学術総会, 27 Sep. 2014, 横浜
  • EGFR transactivation by TNF protects EGFR-TKI, gefitinib induced pulmonary injury in SP-C/TNF transgenic mice, YAMAOKA Toshimitsu;OHMORI Tohru;OHKI Yasunari;MURATA Yasunori;KUSUMOTO Sojiro;ISHIDA Hiroo;SHIRAI Takao;HIROSE Takashi;OHNISHI Tsukasa;SASAKI Yasutsuna, 第73回日本癌学会学術総会, 26 Sep. 2014, 横浜
  • PKCη controls the proliferation of lung adenocarcinoma cells via EGFR and MET endocytic trafficking., OHBA Motoi;TOYA Etsuko;YAMAOKA Toshimitsu;OHMORI Tohru;SASAKI Yasutsuna, 第73回日本癌学会学術総会, 25 Sep. 2014, 横浜
  • Development of Simple Blood Test for Diagnosis of Gastrointestinal and Pancreas Cancer Using Biochip, ITO Hiroaki;HASEGAWA Katsuyuki;HOSOMICHI Kazuyoshi;HASEGAWA Yuuki;INOUE Itsuro;KIMURA Satoshi;OHMORI Tohru;KUDO Shin-ei;MATSUKAWA Masaaki;INOUE Haruhiro, 第73回日本癌学会学術総会, 25 Sep. 2014, 横浜
  • Association of pharmacokinetics or pharmacogenomics with toxicity of erlotinib in patients with advanced NSCLC, HIROSE Takashi;FUJITA Ken-ichi;KUSUMOTO Sojiro;SHIRAI Takao;SUGIYAMA Tomohide;NAKASHIMA Masanao;OHMORI Tohru;SASAKI Yasutsuna;TAMURA Atsuhisa;OHTA Ken, 第12回日本臨床腫瘍学会学術集会, 19 Jul. 2014, 福岡
  • PKCη controls the proliferation of lung adenocarcinoma cells via EGFR and MET endocytic trafficking, OHBA Motoi;TOYA Etsuko;YAMAOKA Toshimitsu;OHMORI Tohru;KUROKI Toshio;SASAKI Yasutsuna, 第12回日本臨床腫瘍学会学術集会, 18 Jul. 2014, 福岡
  • Involvement of protein kinase C eta in the migration and invasion of human lung adenocarcinoma cells, 外谷　衣都子;大場　基;山岡　利光;大森　亨;佐々木　康綱, 第12回日本臨床腫瘍学会学術集会, 18 Jul. 2014, 福岡
  • Tivantinib, shows a synergistic growth-inhibitory effect with erlotinib through enhanced degradation of c-MET protein, OHMORI Tohru;YAMAOKA Toshimitsu;TOYA Etsuko;OHBA Motoi;KOIZUMI Fumiaki;NISHIO Kazuto;AKINAGA Shiro, 第12回日本臨床腫瘍学会学術集会, 17 Jul. 2014, 福岡
  • TNF transactivation of EGFR protects EGFR-TKI induced pulmonary injury in SPC-TNF transgenic mice, 山岡　利光;外谷　衣都子;大場　基;大木　康成;村田　泰規;楠本　壮二郎;石田　博雄;大森　亨;佐々木　康綱, 第12回日本臨床腫瘍学会学術集会, 17 Jul. 2014, 福岡
  • 非小細胞肺癌におけるエルロチニブとゾレドロン酸併用療法の有用性に関する後方視的解析, 大木　康成;廣瀬　敬;白井　崇生;村田　泰規;杉山　智英　　;楠本　壮二郎;石田　博雄;中嶌　賢尚;山岡　利光;奥田　健太郎;大西　司;大森　亨;相良　博典, 第54回日本呼吸器学会学術講演会, 26 Apr. 2014, 大阪
  • Pharmacokinetics, pharmacogenetics and toxicity of erlotinib in patients with non-small cell lung cancer, 廣瀬　敬;藤田　健一;楠本　壮二郎;白井　崇生;村田　泰則;大木　康成;杉山 　智英;石田　博雄;中嶌　賢尚;山岡　利光;奥田　健太郎;大西　司;大森　亨;佐々木　康綱;田村　厚久;大田　健, 第54回日本呼吸器学会学術講演会, 26 Apr. 2014, 大阪
  • 小細胞肺癌患者における末梢血がん細胞数と予後の検討, 白井　崇生;廣瀬　敬;大木　康成;村田　泰規;楠本　壮二郎;杉山　智英;石田　博雄;中鴬　賢尚;山岡　利光;奥田　健太郎;大西　司;大森　亨;相良　博典, 第54回日本呼吸器学会学術講演会, 25 Apr. 2014, 大阪
  • TNF transactivation of EGFR protects EGFR-TKI, gefitinib induced pulmonary epithelial cell apoptosis and injury in TNF transgenic mice., YAMAOKA Toshimitsu;OKI Yasunari;MURATA Yasunori;KUSUMOTO Sojiro;ISHIDA Hiroo;SHIRAI Takao;TOYA Etsuko;OHBA Motoi;FUJITA Ken-ichi;ARATA Satoru;OHMORI Tohru;OHNISHI Tsukasa;SAGARA Hironori;SASAKI Yasutsuna, 105th American Association for Cancer Research annual meeting, 07 Apr. 2014, San Diego
  • Comtribution of miR-205 in gefitinib-resistant lung cancer cell lines, SUZUKI Toshihiro ;NAGASAWA Ikuko;YAMAOKA Toshimitsu;OHMORI Tohru;NISHIO Kazuto;KOYAMA Kiyotaka;OGASAWARA Yuki, The 105th Annual Meeting of the American Association for Cancer Research, 07 Apr. 2014, San Diego
  • Novel methodology of integrated omics analysis by using Surface Enhanced Raman Scattering (SERS): A Preliminary Study, ITO Hiroaki;INOUE Haruhiro;SANDO Norimasa;HASEGAW Katsuyuki;HASEGAWA Yuki;OHMORI Tohru;KIMURA Satoshi;KUDO Shin-ei, 第72回日本癌学会学術総会, 04 Oct. 2013, 横浜
  • The characteristics of dual resistance to EGFR & MET inhibitors in pulmonary adenocarcinoma, PC-9 cells, YAMAOKA Toshimitsu;SUGIYAMA Tomohide;ISHIDA Hiroo;SHIRAI Takao;OKUDA Kentaro;TOYA Etsuko;OHBA Motoi;OHMORI Tohru;SASAKI Yasutsuna, 第72回日本癌学会学術総会, 03 Oct. 2013, 横浜
  • Clinical benefit of 2nd EGFR-TKI retreatment on overall survival in patients with advanced non-small cell lung cancer, NAKASHIMA Masanao;HIROSE Takashi;OHKI Yasunari;MURATA Yasunori;SUGIYAMA Tomohide;ISHIDA Hiroo;OKUDA Kentaro;YAMAOKA Toshimitsu;OHMORI Tohru;OHNISHI Tsukasa, 第11回日本臨床腫瘍学会学術集会, 30 Aug. 2013, 仙台
  • The characteristics of an acquired dural resistance to EGFR & MET inhibitors in non-small cell lung cancer, harboring active mutation of EGFR, YAMAOKA Toshimitsu;ICHIHASHI Yoko;MURATA Yasunori;OKI Yasunari;SUGIYAMA Tomohide;ISHIDA Hiroo;SHIRAI Takao;NAKASHIMA Masanao;OKUDA Kentaro;HIROSE Takashi;OHNISHI Tsukasa;OHMORI Tohru, AACR 104th Annual Meeting 2013, 10 Apr. 2013, Washington, DC
  • A novel c-MET inhibitor, tivantinib, shows an additive growth-inhibitory effect with erlotinib through enhanced degradation of c-MET protein via its recycling pathway, OHMORI Tohru;KANOME Tomoko;YAMAOKA Toshimitsu;HIROSE Takashi;KOIZUMI Fumiaki;NISHIO Kazuto;AKINAGA Shiro, 19th International Charles Heidelberger Symposium on Cancer Research, 14 Feb. 2013, Kagoshima
  • Carboplatin+Paclitaxel+Bevacizumabによる化学療法中にIII度房室ブロックをきたした肺腺癌症例, 白井　崇生;廣瀬　敬;大木　康成;村田　泰規;楠本　壮二郎;杉山　智英;石田　博雄;中嶌　賢尚;奥田　健太郎;大西　司;足立　満;山岡　利光;大森　亨, 第53回日本肺癌学会総会, 08 Nov. 2012, 岡山
  • 進展型小細胞肺癌の生存期間に対するアムルビシンの影響に関する検討., 石田　博雄;大木　康成;村田　泰規;石田　孔子;楠本　壮二郎;杉山　智英;白井　崇生;中嶌　賢尚;山岡　利光;奥田　健太郎;大西　司;大森　亨;廣瀬　敬, 第50回日本癌治療学会学術集会, 25 Oct. 2012, 横浜
  • Cancer vaccination trial novel multiple peptides in previously treated advanced non-small-cell lung cancer (NSCLC), 廣瀬　敬;野田　秀裕;奥田　健太郎;阿部　誠治;大戸　祐治;杉山　智英;石田　博雄;白井　崇生;中嶌　賢尚;山岡　利光;大森　亨;吉田　浩二;中村　祐輔, 第71回日本癌学会学術総会, 19 Sep. 2012, 札幌
  • HSP70 causes EGFR-TKIs resistance in a mutant EGFR expressed non-small cell lung cancer, OHMORI Tohru;YAMAOKA Toshimitsu;ICHIHASHI Yoko;HIROSE Takashi;SAIJO Nagahiro, 第10回日本臨床腫瘍学会学術集会, 27 Jul. 2012, 大阪
  • Cancer Vaccination trial with novel multiple peptides in previously treated advanced non-small cell lung cancer., HIROSE Takashi;NODA Hidehiro;OKUDA Kentaro;ABE Seiji;OTO Yuji;KUSUMOTO Sojiro;SUGIYAMA Tomohide;ISHIDA Hiroo;SHIRAI Takao;NAKASHIMA Masanao;YAMAOKA Toshimitsu;OHMORI Tohru;YOSHIDA Koji;NAKAMURA Yusuke;ADACHI Mitsuru, 2012 Annual Meeting of the American Society of Clinical Oncology, 01 Jun. 2012, Chicago
  • HSP 70 may cause EGFR-TKIs-resistance due to inhibit drug binding to EGFR in the cells that expressed mutant EGFR., OHMORI Tohru;KADOFUKU Tsuyoki;ICHIHASHI Yoko;YAMAOKA Toshimitsu;HIROSE Takashi;ADACHI Mitsuru;SAIJO Nagahiro, AACR 103rd Annual Meeting 2012, 02 Apr. 2012, Chicago
  • Specific epidermal growth factor receptor autophosphorylation sites promote epithelial cell chemotaxis and restitution., YAMAOKA Toshimitsu;FREY Mark;POLK D Brent;OKI Yasunari;MURATA Yasunori;SUGIYAMA Tomohide;KUSUMOTO Sojiro;ISHIDA Hiroo;SHIRAI Takao;NAKASHIMA Masanao;OKUDA Kentaro;OHNISHI Tsukasa;HIROSE Takashi;OHMORI Tohru;ADACHI Mitsuru, AACR 103rd Annual Meeting 2012, 02 Apr. 2012, Chicago

Copyright © MEDIA FUSION Co.,Ltd. All rights reserved.